Ifeanyichukwu Ifechidere: When Fibrinogen isn’t Really Fibrinogen
Ifeanyichukwu Ifechidere, Specialist Biomedical Scientist at Sheffield Teaching Hospitals NHS Foundation Trust, shared a post on LinkedIn:
“When fibrinogen isn’t really fibrinogen…
A ‘normal’ or even elevated fibrinogen result can be reassuring.
But what if that number isn’t telling the full story?
Welcome to one of the most overlooked pitfalls in coagulation testing
The Clauss fibrinogen assay – trusted, but not foolproof
The Clauss method measures functional fibrinogen by assessing clot formation after high thrombin concentration.
But here’s the catch:
It assumes fibrinogen is functionally normal
When it’s not… results can mislead.
Dysfibrinogenemia: the great imitator
In dysfibrinogenemia, fibrinogen antigen levels may be normal… but function is impaired.
What you might see:
Discrepancy between Clauss fibrinogen (low) and antigen (normal)
Unexplained bleeding… or paradoxically, thrombosis
Prolonged clotting times (sometimes subtle, sometimes not)
In other words:
There is fibrinogen present — it just doesn’t work properly
But it’s not always dysfibrinogenemia…
The Clauss assay can be affected by multiple interferences:
- Direct thrombin inhibitors (e.g. dabigatran)
- Heparin (depending on reagent sensitivity)
- High FDPs / D-dimer
- Paraproteins
- Severe inflammation
All of these can – falsely low functional fibrinogen
So what should you do?
- Correlate with clinical context
- Compare functional vs antigen fibrinogen
- Review medications and interferences
- Consider reptilase time or genetic testing if needed
Take-home message
Not all fibrinogen results reflect true functional capacity.
Sometimes, what looks like ‘low fibrinogen’ is actually a measurement limitation – or a dysfunctional molecule hiding in plain sight.
Want more clear, practical insights into coagulation testing pitfalls?”
More posts featuring Ifeanyichukwu Ifechidere on Hemostasis Today.
-
May 26, 2026, 16:45Ashley George: Take the Leap for Thrombosis UK
-
May 26, 2026, 16:40Hamed Helisaz: Machine Learning for Detecting Missing Heart Medications
-
May 26, 2026, 15:32Haroun Gajraj: Brown Marks After Microsclerotherapy – What Every Practitioner Needs to Know
-
May 26, 2026, 15:29Jacqueline van Paassen: Lack of Essential Clinical Data in DOAC Prescriptions in Community Pharmacies
-
May 26, 2026, 15:22Shazmah Shaikh: One Visual Guide to Understand All Major Anticoagulants
-
May 26, 2026, 14:39Chidinma Favour։ Welcome to Day 25 of My 31-Day Stroke Awareness Series
-
May 26, 2026, 14:35Novel Insights Into Congenital and Acquired Coagulopathies – ICHCC
-
May 26, 2026, 14:24Fernanda Orsi: The Growing Impact of Hematology Research in Latin America
-
May 26, 2026, 14:23Rense Buijvoets: What If Clots Could Be Treated Exactly Where They Form?